Rusfertide

Evidence in perspective

Randomized withdrawal after an initial treatment phase addresses maintenance of hematocrit control in selected polycythemia-vera patients. It does not establish benefit for general iron balance or cancer prevention; later-phase results require separate assessment.

Who was studied

Patients with phlebotomy-dependent polycythemia vera in the phase 2 REVIVE trial.

What the sources found

REVIVE reported improved hematocrit control and response during randomized withdrawal.

What remains unknown

Hematocrit control does not by itself establish fewer thromboses or disease modification. Current regulatory status requires separate verification.

How it works

Restricts iron availability for red blood cell production.

Restricts iron availability for red blood cell production. Hematocrit control does not by itself establish fewer thromboses or disease modification. Current regulatory status requires separate verification.

Human trials

This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.

Understanding the evidence

Reported adverse effects

• Safety details remain incomplete in this snapshot; absence of a listed effect does not mean it was excluded.